Media coverage about Repligen (NASDAQ:RGEN) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repligen earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3755614313238 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have effected Accern’s scoring:

RGEN has been the subject of a number of recent research reports. Jefferies Group reiterated a “hold” rating and issued a $40.00 target price on shares of Repligen in a research note on Thursday, September 14th. Stephens reiterated an “overweight” rating and issued a $50.00 target price on shares of Repligen in a research note on Tuesday, September 26th. First Analysis upgraded Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 target price for the company in a research note on Monday, October 2nd. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Thursday, October 5th. Finally, CL King initiated coverage on Repligen in a research note on Monday, November 13th. They issued a “buy” rating and a $41.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Repligen currently has a consensus rating of “Buy” and a consensus price target of $44.38.

Shares of Repligen (RGEN) opened at $37.02 on Thursday. Repligen has a 12 month low of $28.48 and a 12 month high of $46.81. The firm has a market capitalization of $1,610.00, a P/E ratio of 62.75, a price-to-earnings-growth ratio of 2.04 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The firm had revenue of $36.58 million during the quarter, compared to analyst estimates of $35.69 million. During the same quarter last year, the firm earned $0.08 EPS. Repligen’s quarterly revenue was up 48.2% on a year-over-year basis. research analysts forecast that Repligen will post 0.61 earnings per share for the current year.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the completion of the sale, the vice president now owns 36,554 shares in the company, valued at approximately $1,291,818.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.50% of the stock is owned by company insiders.

WARNING: This piece of content was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.